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Objective/background: Tuberculosis (TB) has been declared as a global emergency by the
World Health Organization in 1993 and still remains one of the world’s biggest threats.
Worldwide, 9.6 million people have been estimated to have fallen ill with TB in 2014: 5.4
million men, 3.2 million women, and 1.0 million children. To reduce this burden, detection
and treatment gaps must be addressed and new tools developed (Global TB report 2015).
Methods: Seroreactivity of the purified excretory secretory (ES) antigens ES-31, ES-43, ES-41,
and ES-6 have been assessed in pulmonary TB (fresh, relapse, chronic, and latent), extra-
pulmonary TB, and in human immunodeficiency virus-TB coinfection.
Results: Analysis of immune response to these purified antigens by indirect and sandwich
enzyme-linked immunosorbent assay (ELISA) using sensitive penicillinase enzyme-
immuno assay, showed ES-31 antigen as having good diagnostic potential in pulmonary
TB and in certain groups of extrapulmonary TB, in particular tuberculous lymphadenopa-
thy, tuberculous meningitis, whereas ES-41 was found to be more seroreactive in abdomi-
nal and bone and joint TB. ES-43 antigen was primarily recognized by serum antibodies in
relapse cases, while ES-6 was useful in contacts. Antigen assay was found to be more sen-
sitive than antibody-based assay for detecting TB with human immunodeficiency virus
coinfection. Immunomonitoring for the presence of antigens in TB patients under antitu-
bercular treatment showed that ES-31 antigen assay was useful in determining the effec-
tiveness of therapy and the patient’s compliance. User-friendly peroxidase ELISA has
been standardized for the detection of circulating mycobacterial ES-31 serine protease (free
antigen and immune-complexed antigen) with 70–75% sensitivity and 90% specificity and
with a limit of detection of antigen at 1 ng/2 lL (0.5 lg/mL serum). In-house developed SEVA
TB ELISA assay using a cocktail of antigens (ES-31 + EST-6) and a cocktail of specific anti-
bodies is being routinely done for screening of patients suspected of TB attending Kasturba
Hospital—a tertiary health care center.
The characterization of ES-31 antigen protein showed that ES-31 is a 31-kDa protein anti-
gen with zinc containing serine protease as well as lipase activities and shown to be a
chymotrypsin-like protein which has the catalytic triad responsible for both the activities.
Addition of serine protease inhibitors: (1) pefabloc; (2) 3,4 dichloroisocoumarin; (3) phenyl
methyl sulfonyl fluoride (53–76%); and metallo-protease inhibitors: (1) EDTA; (2) 1,10a. Tel./fax:
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immunogen and drug target against tuberculosphenanthroline (46–61%), lipase inhibitor, orlistat (61%), or anti-ES-31 serine protease anti-
body (89%) inhibited the Mycobacterium tuberculosis (MTB) H37Ra growth in axenic culture
which is further confirmed by a decreased amount of ES-31 protein secreted in the culture
filtrate. The importance of excretory secretory ES-31 protein for the survival of MTB H37Ra
and H37Rv bacilli has been shown by 77% and 78% growth inhibition in macrophage culture
by protease inhibitor pefabloc and was further confirmed by the enhancement of growth of
TB bacilli in the presence of ES-31.
Conclusion: Inhibition of ES-31 leads to the growth inhibition of MTB bacilli, suggesting that
ES-31 is important for entry and multiplication of bacilli and an important drug target for
exploring new drugs for TB based on protease and lipase activities of ES-31 protein.Conflicts of interest
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